VYNE Therapeutics Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“March 11, 2026, the Company received a letter (the “Extension Notice”) from Nasdaq notifying the Company that its request for an extension to regain compliance with the minimum bid price requirement has been granted, and the Company has an additional 180 calendar days, or until September 7, 2026, to regain compliance with the minimum bid price requirement. Nasdaq’s determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of t”
Material Agreements
VYNE Therapeutics Inc. amended Amendment to Agreement and Plan of Merger and Reorganization with Yarrow Merger Sub Corp. and Yarrow Bioscience, Inc. (effective 2026-01-30).
“On January 30, 2026, VYNE Therapeutics Inc., a Delaware corporation (“VYNE”), Yarrow Merger Sub Corp., a Delaware corporation and a wholly-owned subsidiary of VYNE (“Merger Sub”), and Yarrow Bioscience, Inc., a Delaware corporation (“Yarrow”), entered into an amendment (the “Amendment”) to that certain Agreement and Plan of Merger and Reorganization, dated December 17, 2025 (as amended, the “Merger Agreement”), by and among VYNE, Merger Sub and Yarrow.”
Listing & Compliance Notices
VYNE Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“September 11, 2025, VYNE Therapeutics Inc. (the “Company”) received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s common stock (the “Common Stock”) was below $1.00 per share for 30 consecutive business days. The notification does not impact the listing of the Company’s Common Stock on the Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)”
Earnings Releases
VYNE Therapeutics Inc. reported the quarter ended March 31, 2024 results: revenue $0.1 million, net income $6.2 million, EPS $0.15.
“financial statements included in VYNE’s Quarterly Report on Form 10-Q filed today for additional discussion on liquidity and capital resources. Revenues. Revenues totaled $0.1 million for each of the three months ended March 31, 2024 and 2023, consisting of royalty revenue from the Company's royalty agreement with LEO Pharma, to whom VYNE previously licensed”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.